Display options
Cite
Hulin-Curtis SL, Davies JA, Jones R, et al. Histone deacetylase inhibitor trichostatin A sensitises cisplatin-resistant ovarian cancer cells to oncolytic adenovirus. Oncotarget. 2018;9(41):26328-26341doi: 10.18632/oncotarget.25242.
Hulin-Curtis, S. L., Davies, J. A., Jones, R., Hudson, E., Hanna, L., Chester, J. D., & Parker, A. L. (2018). Histone deacetylase inhibitor trichostatin A sensitises cisplatin-resistant ovarian cancer cells to oncolytic adenovirus. Oncotarget, 9(41), 26328-26341. https://doi.org/10.18632/oncotarget.25242
Hulin-Curtis, Sarah L, et al. "Histone deacetylase inhibitor trichostatin A sensitises cisplatin-resistant ovarian cancer cells to oncolytic adenovirus." Oncotarget vol. 9,41 (2018): 26328-26341. doi: https://doi.org/10.18632/oncotarget.25242
Hulin-Curtis SL, Davies JA, Jones R, Hudson E, Hanna L, Chester JD, Parker AL. Histone deacetylase inhibitor trichostatin A sensitises cisplatin-resistant ovarian cancer cells to oncolytic adenovirus. Oncotarget. 2018 May 29;9(41):26328-26341. doi: 10.18632/oncotarget.25242. eCollection 2018 May 29. PMID: 29899862; PMCID: PMC5995174.
Copy Download .nbib Format: NLM
Share it on

Oncotarget. 2018 May 29;9(41):26328-26341. doi: 10.18632/oncotarget.25242. eCollection 2018 May 29.

Histone deacetylase inhibitor trichostatin A sensitises cisplatin-resistant ovarian cancer cells to oncolytic adenovirus.

Oncotarget

Sarah L Hulin-Curtis, James A Davies, Rachel Jones, Emma Hudson, Louise Hanna, John D Chester, Alan L Parker

Affiliations

  1. Division of Cancer and Genetics, School of Medicine, Cardiff University, Heath Park, Cardiff, CF14 4XN, UK.
  2. Velindre Cancer Centre, Whitchurch, Cardiff, CF14, 2TL, UK.

PMID: 29899862 PMCID: PMC5995174 DOI: 10.18632/oncotarget.25242

Abstract

Ovarian cancer is often termed a silent killer due to the late onset of symptoms. Whilst patients initially respond to chemotherapy, they rapidly develop chemo-resistance. Oncolytic adenoviruses (OAds) are promising anti-cancer agents engineered to "hijack" the unique molecular machinery of cancer cells enabling tumour-selective viral replication. This allows spread to adjacent cells and amplification of oncolysis within the tumour. OAds represent an excellent opportunity for ovarian cancer therapy via intra-peritoneal delivery, however the efficacy of OAds thus far is limited. Here, we evaluate chromatin (histone) modification in chemo-resistant cells and its relationship to Ad efficacy (wild-type or oncolytic Ad). In contrast to cisplatin-sensitive A2780 cells that show an efficient reduction of cell viability by Ad in the presence of cisplatin, cisplatin-resistant A2780/cp70 cells show diminishing Ad-mediated reduction of cell viability with escalating doses of cisplatin. Histone deacetylase (HDAC)-2 and to a lesser extent HDAC1 were up-regulated in cisplatin-resistant but not cisplatin-sensitive cells. Cisplatin-resistant cells treated with a pan-HDAC inhibitor trichostatin A (TsA) significantly enhanced Ad-mediated reduction of cell viability in the presence of cisplatin. Cells treated with TsA alone did not reduce cell viability suggesting these findings are Ad-dependent. Thus, we identify HDAC inhibition as a potential means to sensitise cisplatin-resistant ovarian cancer cells to virotherapies, an observation that may offer improved outcomes for patients with late stage, chemotherapy-resistant ovarian cancer.

Keywords: cisplatin-resistance; histone deacetylase inhibitor; oncolytic adenovirus; ovarian cancer

Conflict of interest statement

CONFLICTS OF INTEREST None of the authors declare conflicts of interest.

References

  1. Exp Cell Res. 2006 Feb 1;312(3):256-65 - PubMed
  2. Nat Rev Drug Discov. 2014 Sep;13(9):673-91 - PubMed
  3. Oncotarget. 2015 Aug 21;6(24):19976-89 - PubMed
  4. Cancer Gene Ther. 2004 Jul;11(7):477-86 - PubMed
  5. Oncolytic Virother. 2016 Jan 06;5:1-13 - PubMed
  6. Vaccines (Basel). 2016 Nov 14;4(4): - PubMed
  7. J Clin Invest. 2014 Jan;124(1):30-9 - PubMed
  8. J Hyg (Lond). 1982 Aug;89(1):155-61 - PubMed
  9. J Natl Cancer Inst. 2006 Mar 1;98(5):298-300 - PubMed
  10. Nat Biotechnol. 2008 Jan;26(1):37-53 - PubMed
  11. Clin Cancer Res. 2006 Nov 15;12(22):6737-47 - PubMed
  12. Mol Oncol. 2015 Apr;9(4):791-805 - PubMed
  13. Mol Cancer Ther. 2007 Feb;6(2):496-505 - PubMed
  14. Oncogene. 2000 Jan 6;19(1):2-12 - PubMed
  15. Nat Genet. 2005 Apr;37(4):391-400 - PubMed
  16. Blood. 2006 Oct 15;108(8):2554-61 - PubMed
  17. PLoS One. 2015 May 18;10(5):e0127058 - PubMed
  18. Nat Med. 2000 Aug;6(8):879-85 - PubMed
  19. PLoS One. 2012;7(10):e46858 - PubMed
  20. Semin Oncol. 2006 Apr;33(2 Suppl 6):S3-11 - PubMed
  21. Viruses. 2016 Jan 06;8(1):null - PubMed
  22. Mol Ther. 2008 Jun;16(6):1006-8 - PubMed
  23. Viruses. 2015 Nov 24;7(11):6009-42 - PubMed
  24. Cancer Sci. 2017 May;108(5):831-837 - PubMed
  25. Oncotarget. 2016 May 10;7(19):27926-37 - PubMed
  26. J Virol. 2009 Jan;83(1):479-83 - PubMed
  27. Hum Gene Ther. 2015 May;26(5):320-9 - PubMed
  28. Clin Transl Oncol. 2013 Mar;15(3):182-8 - PubMed
  29. Science. 1997 Feb 28;275(5304):1320-3 - PubMed
  30. Biotechniques. 2008 Dec;45(6):659-62, 664-8 - PubMed
  31. J Clin Oncol. 2015 Sep 1;33(25):2780-8 - PubMed
  32. Br J Cancer. 2016 Feb 16;114(4):357-61 - PubMed
  33. Mol Cell Biol. 2007 Jul;27(13):4784-95 - PubMed
  34. Biochemistry (Mosc). 2016 Jul;81(7):700-8 - PubMed
  35. Virus Genes. 2017 Oct;53(5):692-699 - PubMed
  36. Cancer Gene Ther. 2001 Mar;8(3):168-75 - PubMed
  37. Br J Cancer. 2013 Feb 19;108(3):579-86 - PubMed
  38. Cancer Res. 2000 Nov 15;60(22):6359-66 - PubMed
  39. Oncogene. 2010 Oct 14;29(41):5619-29 - PubMed
  40. Gynecol Oncol. 2002 May;85(2):260-5 - PubMed
  41. J Clin Invest. 2014 Jan;124(1):14-6 - PubMed
  42. Cell. 2008 Feb 8;132(3):397-409 - PubMed
  43. Int J Cancer. 2010 Sep 1;127(6):1332-46 - PubMed
  44. Mol Cancer Ther. 2016 Feb;15(2):299-312 - PubMed
  45. Oncol Rep. 2015 Nov;34(5):2238-50 - PubMed
  46. Curr Opin Virol. 2016 Dec;21:9-15 - PubMed
  47. Genes Dis. 2017 Jun;4(2):43-63 - PubMed
  48. Eur J Cancer. 2002 Sep;38(14):1917-26 - PubMed
  49. BMC Genomics. 2006 Apr 25;7:90 - PubMed
  50. Nature. 2016 Apr 14;532(7598):162-4 - PubMed
  51. Oncotarget. 2016 Jan 26;7(4):4695-711 - PubMed
  52. J Cell Biochem. 2009 Jul 1;107(4):600-8 - PubMed
  53. J Cancer Prev. 2013 Sep;18(3):227-34 - PubMed

Publication Types